MicraAV Versus Dual-Chamber Transvenous Pacemakers in Patients with Atrioventricular Block Following Transcatheter Aortic Valve Replacement: A 12-Month Single-Center Retrospective Study
- 1Department of Cardiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8551, Kanagawa, Japan
Abstract
Background: Data directly comparing the atrioventricular (AV)-synchronous leadless pacemaker (MicraAV) with a dual-chamber transvenous pacemaker (DDD) after transcatheter aortic valve replacement (TAVR) remain limited. Methods: We retrospectively studied patients undergoing pacemaker implantation for advanced or complete AV block within one month after TAVR at a single Japanese center between 2016 and 2025. After exclusions, the primary cohort comprised 74 patients (MicraAV, n = 29; DDD, n = 45). Clinical outcomes were assessed through 12 months, with death treated as a competing event for nonfatal outcomes. Device and echocardiographic parameters were evaluated longitudinally. Results: MicraAV recipients were less frequently female than DDD recipients (48.3% vs. 75.6%, p = 0.025). In the MicraAV and DDD groups, respectively, all-cause mortality was 6.9% and 6.7% (unadjusted HR, 1.12; 95% CI, 0.19–6.68; p = 0.904), heart failure rehospitalization occurred in 17.2% and 4.4% (subdistribution HR, 4.44; 95% CI, 0.86–22.92; p = 0.075), and device-related complications occurred in 6.9% and 4.4% (subdistribution HR, 1.60; 95% CI, 0.23–11.40; p = 0.636). The median MicraAV tracking index was 88.4% [IQR, 66.4–95.1]. No significant group-by-time interactions were observed for device electrical performance or echocardiographic left ventricular parameters. Tricuspid regurgitation worsened over time in the MicraAV group. Conclusions: All-cause mortality and device-related complications were infrequent in both groups, whereas heart failure rehospitalization occurred more frequently in the MicraAV group. Given the small number of events and wide confidence intervals, these findings should be considered exploratory and require confirmation in larger contemporary cohorts.
Related
- External validation of the D-PACE score for predicting late high-grade atrioventricular block after transcatheter aortic valve replacement in a Colombian cohort
- Outcomes of Surgical Versus Transcatheter Mitral Valve Repair or Replacement in Patients With Myocardial Infarction and Concomitant Mitral Regurgitation: A Retrospective Analysis of Real-World Data
- Kidney Function Trajectories in Patients with and Without Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement: A Single-Retrospective Cohort Study
- Clinical Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors After Transcatheter Aortic Valve Replacement in Patients With Diabetes: A Global Retrospective Study
- Surgical aortic valve replacement-level aortotomy for self-expanding transcatheter aortic valve explantation
BibTeX
@article{fukunaga2026micraav,
title = {{MicraAV Versus Dual-Chamber Transvenous Pacemakers in Patients with Atrioventricular Block Following Transcatheter Aortic Valve Replacement: A 12-Month Single-Center Retrospective Study}},
author = {Hiroshi Fukunaga and Kenichi Sasaki and Akira Kasagawa and Daisuke Togashi and Toshiya Yoshida and Ikutaro Nakajima and Shingo Kuwata and Masaki Izumo and Tomoo Harada and Yoshihiro J. Akashi},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207831},
url = {https://www.mdpi.com/2077-0383/15/20/7831},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MicraAV Versus Dual-Chamber Transvenous Pacemakers in Patients with Atrioventricular Block Following Transcatheter Aortic Valve Replacement: A 12-Month Single-Center Retrospective Study
AU - Hiroshi Fukunaga
AU - Kenichi Sasaki
AU - Akira Kasagawa
AU - Daisuke Togashi
AU - Toshiya Yoshida
AU - Ikutaro Nakajima
AU - Shingo Kuwata
AU - Masaki Izumo
AU - Tomoo Harada
AU - Yoshihiro J. Akashi
PY - 2026
DA - 2026/10/10
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207831
UR - https://www.mdpi.com/2077-0383/15/20/7831
AB - Background: Data directly comparing the atrioventricular (AV)-synchronous leadless pacemaker (MicraAV) with a dual-chamber transvenous pacemaker (DDD) after transcatheter aortic valve replacement (TAVR) remain limited. Methods: We retrospectively studied patients undergoing pacemaker implantation for advanced or complete AV block within one month after TAVR at a single Japanese center between 2016 and 2025. After exclusions, the primary cohort comprised 74 patients (MicraAV, n = 29; DDD, n = 45). Clinical outcomes were assessed through 12 months, with death treated as a competing event for nonfatal outcomes. Device and echocardiographic parameters were evaluated longitudinally. Results: MicraAV recipients were less frequently female than DDD recipients (48.3% vs. 75.6%, p = 0.025). In the MicraAV and DDD groups, respectively, all-cause mortality was 6.9% and 6.7% (unadjusted HR, 1.12; 95% CI, 0.19–6.68; p = 0.904), heart failure rehospitalization occurred in 17.2% and 4.4% (subdistribution HR, 4.44; 95% CI, 0.86–22.92; p = 0.075), and device-related complications occurred in 6.9% and 4.4% (subdistribution HR, 1.60; 95% CI, 0.23–11.40; p = 0.636). The median MicraAV tracking index was 88.4% [IQR, 66.4–95.1]. No significant group-by-time interactions were observed for device electrical performance or echocardiographic left ventricular parameters. Tricuspid regurgitation worsened over time in the MicraAV group. Conclusions: All-cause mortality and device-related complications were infrequent in both groups, whereas heart failure rehospitalization occurred more frequently in the MicraAV group. Given the small number of events and wide confidence intervals, these findings should be considered exploratory and require confirmation in larger contemporary cohorts.
SN - 2077-0383
ER -